<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03043365</url>
  </required_header>
  <id_info>
    <org_study_id>170050</org_study_id>
    <secondary_id>17-H-0050</secondary_id>
    <nct_id>NCT03043365</nct_id>
  </id_info>
  <brief_title>Effect of Fish Oil Enriched In Omega-11 Fatty Acid On Lipoprotein Metabolism In Adults</brief_title>
  <official_title>Effect of Fish Oil Enriched In Omega-11 Fatty Acid On Lipoprotein Metabolism In Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background:&#xD;
&#xD;
      Fish oils are known to be beneficial to health and believed to be cardio-protective. Omega-3&#xD;
      fatty acid is the most known fish oil available in the market. LCMUFA (long-chain&#xD;
      monounsaturated fatty acids) is also a fish oil but it is derived from fish that consumes a&#xD;
      diet rich in omega-11 fatty acid. Researchers want to study omega-11 fatty acid enriched fish&#xD;
      oil and understand its effect on cardiovascular health.&#xD;
&#xD;
      Objective:&#xD;
&#xD;
      To understand the effects of LCMUFA from fish oil on cardiovascular health.&#xD;
&#xD;
      Eligibility:&#xD;
&#xD;
      Healthy volunteers ages 18 and older with no history of cardiovascular disease&#xD;
&#xD;
      Design:&#xD;
&#xD;
      Participants will be screened with:&#xD;
&#xD;
        -  Medical history&#xD;
&#xD;
        -  Physical exam&#xD;
&#xD;
        -  Fasting blood and urine tests&#xD;
&#xD;
        -  Optional stool sample&#xD;
&#xD;
        -  Questions about their diet, exercise, and the types of medicines and dietary supplements&#xD;
           they take&#xD;
&#xD;
        -  7-day food diary&#xD;
&#xD;
        -  Cardio-Ankle Vascular Index (CAVI): Blood pressure is taken in the arms and legs. The&#xD;
           heart is monitored.&#xD;
&#xD;
        -  After the screening visit, participants will take 4 gel capsules, 3 times a day after&#xD;
           meals, for 8-10 weeks.&#xD;
&#xD;
        -  Electrocardiogram (EKG)&#xD;
&#xD;
      Participants will have 3 additional visits. All include repeats of the screening tests.&#xD;
&#xD;
      Visit 2 is 8 weeks after the screening visit. Participants will stop taking the capsules for&#xD;
      8 weeks after this visit.&#xD;
&#xD;
      Visit 3 is at least 16 weeks after starting the supplement. Participants will take 4&#xD;
      capsules, 3 times a day after meals, for 8 weeks after this visit.&#xD;
&#xD;
      Visit 4 is 8 weeks after starting the second supplement.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Serum cholesterol is transported by lipoproteins, such as very low-density lipoprotein&#xD;
      (VLDL), low-density lipoproteins (LDL) and high-density lipoproteins (HDL), which vary in&#xD;
      their relationship to cardiovascular disease risk. LDL, for example, is proatherogenic,&#xD;
      whereas HDL is cardio-protective. Long-chain monounsaturated fatty acids (LCMUFA), fatty&#xD;
      acids over 18 carbons in length with a single double bond, have been shown in mice to&#xD;
      decrease proatherogenic lipoproteins, such as LDL, and reduce atherosclerosis. This study&#xD;
      will test the hypothesis that LCMUFA supplementation in humans will favorably alter the&#xD;
      lipoprotein lipid profile in regard to cardiovascular disease risk. In addition, we will&#xD;
      assess other parameters related to lipoprotein composition and function, as well as other&#xD;
      biomarkers related to coagulation and inflammation, which have previously been shown to be&#xD;
      affected by supplementation with omega-3 fatty acids.&#xD;
&#xD;
      This clinical research project is designed as a pilot, randomized, double-blinded, crossover&#xD;
      study that will investigate the effect of a fish oil enriched with LCMUFA on lipoprotein&#xD;
      metabolism. Subjects will receive control fish oil enriched in oleic acid, a monounsaturated&#xD;
      fatty acid (C18:1), or a fish oil supplement produced from Saury fish (rich in LCMUFA) for&#xD;
      approximately 8-10 weeks, with a wash out period of 8-10 weeks between the two arms of the&#xD;
      study. The study consists of 4 outpatient visits when laboratory or research samples and CAVI&#xD;
      tests will be performed. A 7-day food diary, pill count, and red cell membrane fatty acid&#xD;
      levels will be monitored to assess compliance.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 15, 2017</start_date>
  <completion_date type="Actual">November 21, 2019</completion_date>
  <primary_completion_date type="Actual">May 29, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes From Baseline in Lipid Profile at 8 Weeks</measure>
    <time_frame>baseline and 8 weeks</time_frame>
    <description>The primary outcome measures of this study will be the change from baseline to end of intervention period (8 weeks) in the lipid profile (total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C)) for the control and research supplement groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes Lipoprotein Particle Number, Composition and Size (sdLDL, LDL-TG, ApoE-HDL, ApoA-I, ApoB)</measure>
    <time_frame>baseline and 8 weeks</time_frame>
    <description>Secondary outcome measurements will be changes in proteomics, lipoprotein particle number, high-density lipoprotein (HDL) functional test (i.e. efflux study) composition and size. Secondary outcome will measure the following: Small dense low density lipoprotein (sdLDL); Low-Density Lipoprotein Triglycerides (LDL-TG); Apolipoprotein E-containing high-density lipoprotein (ApoE-HDL); apolipoprotein A-I (ApoA-I); Apolipoprotein B (ApoB).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes Lipoprotein Particle Number, Composition and Size in Oxidized Low-density Lipoprotein (oxLDL)</measure>
    <time_frame>baseline and 8 weeks</time_frame>
    <description>Secondary outcome measurements will be changes in proteomics, lipoprotein particle number, high-density lipoprotein (HDL) functional test (i.e. efflux study) composition and size.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Lipoprotein Metabolism</condition>
  <condition>PCSK9</condition>
  <condition>Proteomics</condition>
  <arm_group>
    <arm_group_label>Arm 1: Control Fish Oil first, then Saury Oil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects randomized to the control fish oil arm will take the equivalent to 3g of control /day (12 gel capsules/day) for 8 plus or less 2 weeks and crossover to the LCMUFA-rich saury oil capsule arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2: Saury Oil first, then Control Fish Oil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects randomized to the LCMUFA-rich saury oil arm will take the equivalent to 3g of control/day (12 gel capsules/day) for 8 plus or less 2 weeks and crossover to the control fish oil capsule arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Washout Period</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>8 week washout period to occur between week 8 and week 16. No study supplement taken by subject at this time.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>control fish oil</intervention_name>
    <description>4 capsules, 3 times a day after meals</description>
    <arm_group_label>Arm 1: Control Fish Oil first, then Saury Oil</arm_group_label>
    <other_name>DHA, docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA), EPA (fish oils)</other_name>
    <other_name>fish oils, marine oils, N3 fatty acids, omega 3 polyunsaturated fatty acid (PUFA), polyunsaturated fatty acids,</other_name>
    <other_name>PUFA, W3 fatty acids</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LCMUFA-rich saury oil</intervention_name>
    <description>4 capsules, 3 times a day after meals</description>
    <arm_group_label>Arm 2: Saury Oil first, then Control Fish Oil</arm_group_label>
    <other_name>long-chain monounsaturated fatty acids</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:&#xD;
&#xD;
          -  Male and female participants 18 years of age or above.&#xD;
&#xD;
          -  Subject must be healthy, with no known history of cardiovascular disease.&#xD;
&#xD;
          -  Pre-menopausal or women of childbearing potential must be non-lactating and using an&#xD;
             effective form of birth control during the course of the study.&#xD;
&#xD;
          -  Subject understands protocol and provides written, informed consent in addition to a&#xD;
             willingness to comply with specified follow-up evaluations.&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
          -  Pregnancy, planned pregnancy (within the study period) or women currently&#xD;
             breastfeeding.&#xD;
&#xD;
          -  Subjects with weight changes greater than 20% over the past 3 months.&#xD;
&#xD;
          -  Subjects planning a significant change in diet or exercise levels.&#xD;
&#xD;
          -  Subjects already consuming more than 1.5 g per day of eicosapentaenoic acid (EPA) or&#xD;
             docosahexaenoic acid (DHA) in any form.&#xD;
&#xD;
          -  Known sensitivity or allergy to fish, shellfish or omega-3 fatty acids supplements&#xD;
&#xD;
          -  Subjects with known bleeding disorders (for example, Hemophilia)&#xD;
&#xD;
          -  Subjects previously diagnosed with atrial fibrillation&#xD;
&#xD;
          -  Subjects with clinically diagnosed hepatic disease (including but not limited to auto&#xD;
             immune disease, hepatitis and cirrhosis)&#xD;
&#xD;
          -  Subjects with chronic diarrhea, gastric bypass or lap-band procedures, ostomies, bowel&#xD;
             motility problems, or other conditions that could affect intestinal fat absorption&#xD;
&#xD;
          -  Subjects with any acute and life-threatening condition, such as prior sudden cardiac&#xD;
             arrest, acute myocardial infarction (last three months), stroke, embolism&#xD;
&#xD;
          -  Liver enzymes (aspartate aminotransferase (AST) or alanine aminotransferase (ALT))&#xD;
             levels above 3x upper limit of normal&#xD;
&#xD;
          -  Subjects with a thyroid-stimulating hormone (TSH) greater than 1.5x upper limits of&#xD;
             normal (ULN) or clinical evidence of hypo or hyperthyroidism&#xD;
&#xD;
          -  Subjects taking supplements or medications that affect lipoproteins for at least the&#xD;
             past 8 weeks, such as fish oil supplements, bile-acid sequestrants, plant sterol&#xD;
             supplements, fibrates, statins or Niacin.&#xD;
&#xD;
          -  Subjects with hemoglobin &lt;10g/dL&#xD;
&#xD;
          -  Subject with platelet counts &lt;60x103/microliter&#xD;
&#xD;
          -  Subjects with uncontrolled hypertension (resting blood pressure &gt; 160 mmHg systolic&#xD;
             and /or &gt; 100 mm Hg diastolic)&#xD;
&#xD;
          -  Subject with uncontrolled diabetes (hemoglobin A1c (HbA1c) greater than or equal to&#xD;
             10)&#xD;
&#xD;
          -  Subjects who consume excessive alcohol (binge drinking on 5 or more days in the past&#xD;
             month)&#xD;
&#xD;
          -  Subject participating in other clinical studies and/or receiving other investigational&#xD;
             drug products prior to randomization&#xD;
&#xD;
          -  Subject taking PCSK9 inhibitors within 8 weeks prior to enrollment&#xD;
&#xD;
          -  Subjects being treated with tamoxifen, estrogens, or progestins that have not been&#xD;
             stable for &gt;4 weeks.&#xD;
&#xD;
          -  Subjects initiating new medications or patients on multiple medications may also be&#xD;
             excluded according to investigator discretion&#xD;
&#xD;
          -  Anticipated surgery during the study period&#xD;
&#xD;
          -  Blood donation in the last 2 weeks or planned blood donation during the study&#xD;
&#xD;
          -  Subjects requiring regular transfusions for any reason&#xD;
&#xD;
          -  Subjects may also be excluded for any reason that may compromise their safety or the&#xD;
             accuracy of research data.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marcelo J Amar, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Heart, Lung, and Blood Institute (NHLBI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>February 3, 2017</study_first_submitted>
  <study_first_submitted_qc>February 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2017</study_first_posted>
  <results_first_submitted>May 26, 2020</results_first_submitted>
  <results_first_submitted_qc>August 3, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 12, 2020</results_first_posted>
  <last_update_submitted>August 3, 2020</last_update_submitted>
  <last_update_submitted_qc>August 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Fish Oils</keyword>
  <keyword>Long Chain Monounsaturated Fatty Acids (LCMUFA)</keyword>
  <keyword>Lipoproteins</keyword>
  <keyword>Cardiovascular Disease</keyword>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 2, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/65/NCT03043365/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Thirty-seven healthy volunteers were recruited from June 2017 through March 2018 at the National Institutes of Health (NIH) (Bethesda, MD)</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Arm 1: Control Fish Oil Arm Then Saury Oil</title>
          <description>Subjects randomized to the control fish oil arm will take the equivalent to 3g of control /day (12 gel capsules/day) for 8 plus or less 2 weeks and cross-over to the Long Chain Monounsaturated Fatty Acids (LCMUFA)-rich saury oil capsule arm control fish oil: 4 capsules, 3 times a day after meals</description>
        </group>
        <group group_id="P2">
          <title>Arm 2 - Saury Oil Arm Then Control Fish Oil</title>
          <description>Subjects randomized to the LCMUFA-rich saury oil arm will take the equivalent to 3g of control/day (12 gel capsules/day) for 8 plus or less 2 weeks and crossover to the control fish oil capsule arm Long Chain Monounsaturated Fatty Acids (LCMUFA)-rich saury oil: 4 capsules, 3 times a day after meals</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Weeks 0 to Week 8</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Week 8 to Week 16 - Washout Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Week 16 to Week 24</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm 1: Control Fish Oil First, Then Saury Oil</title>
          <description>Subjects randomized to the control fish oil arm will take the equivalent to 3g of control /day (12 gel capsules/day) for 8 plus or less 2 weeks and crossover to the LCMUFA-rich saury oil capsule arm control fish oil: 4 capsules, 3 times a day after meals</description>
        </group>
        <group group_id="B2">
          <title>Arm 2:Saury Oil First, Then Control Fish Oil</title>
          <description>Subjects randomized to the LCMUFA-rich saury oil arm will take the equivalent to 3g of control/day (12 gel capsules/day) for 8 plus or less 2 weeks and crossover to the control fish oil capsule arm LCMUFA-rich saury oil: 4 capsules, 3 times a day after meals</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="17"/>
            <count group_id="B3" value="37"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35" spread="12.6"/>
                    <measurement group_id="B2" value="32.3" spread="12.9"/>
                    <measurement group_id="B3" value="34.8" spread="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Changes From Baseline in Lipid Profile at 8 Weeks</title>
        <description>The primary outcome measures of this study will be the change from baseline to end of intervention period (8 weeks) in the lipid profile (total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C)) for the control and research supplement groups.</description>
        <time_frame>baseline and 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Control Fish Oil Arm</title>
            <description>Subjects randomized to the control fish oil arm will take 3g of control /day (12 gel capsules/day) for 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - Saury Oil Arm</title>
            <description>Subjects randomized to the LCMUFA-rich saury oil arm will take the equivalent to 3g of control/day (12 gel capsules/day) for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Changes From Baseline in Lipid Profile at 8 Weeks</title>
          <description>The primary outcome measures of this study will be the change from baseline to end of intervention period (8 weeks) in the lipid profile (total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C)) for the control and research supplement groups.</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TG (mg/dL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52" spread="21.1"/>
                    <measurement group_id="O2" value="56.1" spread="26.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TC (mg/dL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="184.3" spread="45.6"/>
                    <measurement group_id="O2" value="181.7" spread="50.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL-C (mg/dL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.9" spread="16.9"/>
                    <measurement group_id="O2" value="68.7" spread="19.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL-C (mg/dL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102.7" spread="45.2"/>
                    <measurement group_id="O2" value="98.6" spread="50.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes Lipoprotein Particle Number, Composition and Size (sdLDL, LDL-TG, ApoE-HDL, ApoA-I, ApoB)</title>
        <description>Secondary outcome measurements will be changes in proteomics, lipoprotein particle number, high-density lipoprotein (HDL) functional test (i.e. efflux study) composition and size. Secondary outcome will measure the following: Small dense low density lipoprotein (sdLDL); Low-Density Lipoprotein Triglycerides (LDL-TG); Apolipoprotein E-containing high-density lipoprotein (ApoE-HDL); apolipoprotein A-I (ApoA-I); Apolipoprotein B (ApoB).</description>
        <time_frame>baseline and 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Control Fish Oil Arm</title>
            <description>Subjects randomized to the control fish oil arm will take the equivalent to 3g of control /day (12 gel capsules/day) for 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - Saury Oil Arm</title>
            <description>Subjects randomized to the LCMUFA-rich saury oil arm will take the equivalent to 3g of control/day (12 gel capsules/day) for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Changes Lipoprotein Particle Number, Composition and Size (sdLDL, LDL-TG, ApoE-HDL, ApoA-I, ApoB)</title>
          <description>Secondary outcome measurements will be changes in proteomics, lipoprotein particle number, high-density lipoprotein (HDL) functional test (i.e. efflux study) composition and size. Secondary outcome will measure the following: Small dense low density lipoprotein (sdLDL); Low-Density Lipoprotein Triglycerides (LDL-TG); Apolipoprotein E-containing high-density lipoprotein (ApoE-HDL); apolipoprotein A-I (ApoA-I); Apolipoprotein B (ApoB).</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>sdLDL (mg/dL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.7" spread="16.4"/>
                    <measurement group_id="O2" value="29" spread="17.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL-TG (mg/dL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.4" spread="6.3"/>
                    <measurement group_id="O2" value="14.7" spread="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ApoE-HDL (mg/dL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3" spread="1.7"/>
                    <measurement group_id="O2" value="6.5" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ApoA-I (mg/dL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="158.3" spread="26.8"/>
                    <measurement group_id="O2" value="156.1" spread="30.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ApoB (mg/dL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.4" spread="31.1"/>
                    <measurement group_id="O2" value="89" spread="33.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes Lipoprotein Particle Number, Composition and Size in Oxidized Low-density Lipoprotein (oxLDL)</title>
        <description>Secondary outcome measurements will be changes in proteomics, lipoprotein particle number, high-density lipoprotein (HDL) functional test (i.e. efflux study) composition and size.</description>
        <time_frame>baseline and 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Control Fish Oil Arm</title>
            <description>Subjects randomized to the control fish oil arm will take the equivalent to 3g of control /day (12 gel capsules/day) for 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - Saury Oil Arm</title>
            <description>Subjects randomized to the LCMUFA-rich saury oil arm will take the equivalent to 3g of control/day (12 gel capsules/day) for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Changes Lipoprotein Particle Number, Composition and Size in Oxidized Low-density Lipoprotein (oxLDL)</title>
          <description>Secondary outcome measurements will be changes in proteomics, lipoprotein particle number, high-density lipoprotein (HDL) functional test (i.e. efflux study) composition and size.</description>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.3" spread="24.8"/>
                    <measurement group_id="O2" value="72.9" spread="26.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Arm 1: Control Fish Oil Arm</title>
          <description>Subjects randomized to the control fish oil arm will take the equivalent to 3g of control /day (12 gel capsules/day) for 8 weeks</description>
        </group>
        <group group_id="E2">
          <title>Arm 2: Saury Oil Arm</title>
          <description>Subjects randomized to the LCMUFA-rich saury oil arm will take the equivalent to 3g of control/day (12 gel capsules/day) for 8 weeks</description>
        </group>
        <group group_id="E3">
          <title>Washout Period</title>
          <description>No intervention administer to participants.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE version 4.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Toe Injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Plantar fasciitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash acneiform</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Skin biopsy of left leg</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Marcelo J. Amar, M.D. Principal Investigator, NIH, NHLBI</name_or_title>
      <organization>National Heart Lung and Blood Institute (NHLBI)</organization>
      <phone>301-402-0521</phone>
      <email>mamar@nhlbi.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

